SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending due to disappointing Alzheimer's trial results, leading to a significant stock drop and increased market volatility. The community is debating whether this presents a buying opportunity or signals further decline, while some speculate about potential acquisitions to bolster their pipeline. Discussions also involve comparisons to competitor Eli Lilly and the impact of potential price cuts.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending following reports of potential changes to the Affordable Care Act, with community members discussing the implications of a possible rollback of subsidies. Some believe the company is well-positioned regardless of policy changes, while others express concern about potential impacts on their business model. Traders are actively debating potential support and resistance levels amid the uncertainty.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WRD is trending due to strong revenue growth driven by its robotaxi business and global expansion, particularly in the Middle East, with discussions focused on its autonomous vehicle technology and partnerships with companies like Uber and Grab. Community members are weighing WRD's potential against competitors like Pony.ai, considering factors such as market capitalization and institutional investment. The stock's high volatility and sensitivity to news are also key discussion points.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as traders digest news of its Qwen AI app reaching 10 million downloads, sparking debate about its competitive positioning against rivals like ChatGPT. Community discussions are centered on the company's AI strategy, potential regulatory risks, and upcoming earnings. Bullish investors are expressing confidence in Alibaba's long-term growth potential while bearish traders cite concerns about US-China relations and potential policy impacts.

Monad

Monad is trending due to its recent launch on Coinbase, stirring mixed reactions within the community. While some investors express excitement and optimism about its potential, others are wary of its performance and pre-market trading activity, with some users calling it a scam. The discussions also revolve around the token's distribution and its potential for staking rewards.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as discussions swirl around the company potentially allowing Bitcoin and Ethereum as loan collateral, a move seen by some as a major shift despite CEO Jamie Dimon's past skepticism towards crypto. The community is also buzzing about a possible silent war between JPMorgan and MicroStrategy ($MSTR), with some calling for a boycott of the bank. Technical analysis suggests JPM's chart indicates a possible support bounce or breakdown.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending as investors await Phase 3 data for its DMD treatment, Deramiocel, with community discussions focusing on the potential for positive results and regulatory approval. Community members are weighing the chances of success in PUL and LVEF endpoints, while some express concern over delays and market volatility. Broader discussion includes potential partnership opportunities and the impact of FDA decisions on rare disease therapies.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet's GOOG is trending as its Gemini 3 AI model launches, outperforming competitors and sparking community excitement about Google's potential dominance in the AI space. Community members are discussing the implications of Gemini 3 and Google's overall growth potential, with some predicting significant price increases. The rise comes amid broader discussions about AI infrastructure and Google's competitive positioning against other tech giants.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

MSI is trending due to community focus on technical analysis, particularly positive divergence and significant dark pool activity suggesting a potential oversold bounce. Traders are pointing to a large dark pool print as a sign of a bottom and reversal. The stock's oversold condition and potential for a bounce are key talking points.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

Molina Healthcare is trending as investors assess its recent earnings report and reduced guidance, with some viewing the dip as a buying opportunity due to the company's underlying value and potential for a rebound. Community discussion revolves around the impact of ACA subsidies, potential short squeezes, and comparisons to sector peers like Centene and UnitedHealth. Several analysts have adjusted their ratings, contributing to the ongoing debate around the stock's future performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Vanguard Russell 1000 Growth ETF (VONG) Be on Your Investing Radar?

Viking Therapeutics has faced a tough start to 2025, with its shares down more than 22% as of Thursday’s close.On Wednesday, the San Diego-based clinical-stage biopharmaceutical company reported a fourth-quarter loss of $0.32 per share, which was wider than the expected $0.27.&nbsp;Viking is still in the development phase and has yet to generate revenue, a common scenario for small- and mid-cap biotech startups.As of Dec. 31, 2024, Viking had $903 million in cash and investments, which it says will help it achieve critical clinical milestones, including completing Phase 3 trials for its subcutaneous version of VK2735, an obesity therapy.In a recent Stocktwits poll, retail traders were asked for their stock price expectations for Viking by the end of 2025.&nbsp;A significant 35%&nbsp;of the poll respondents believe the stock will close below $30, while 32% expect it to rise above $80, a level last seen in late October.&nbsp;Meanwhile, 18% anticipate the stock will end the year between $50 and $80, and 15% see it landing between $30 and $50.<figure class="image"><img style="aspect-ratio:1306/650;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VKTX_price_prediction_Stocktwits_poll_on_Feb_7_30c9d66fd7.png" alt="VKTX price prediction Stocktwits poll on Feb 7.png" width="1306" height="650"><figcaption>VKTX price prediction Stocktwits poll on Feb 7</figcaption></figure>In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735, a Phase 1 trial of an oral tablet form of VK2735, a Phase 2b study for VK2809 to treat metabolic steatohepatitis (MASH) and fibrosis, and a Phase 1b study of VK0214 for X-linked adrenoleukodystrophy.&nbsp;However, there is growing concern over increased competition in the weight-loss drug market, with Novo Nordisk and Eli Lilly dominating the sector.William Blair and Oppenheimer analysts have speculated that Viking could be an acquisition target for a larger company.&nbsp;This premise gained momentum earlier this week when Novartis CEO Vas Narasimhan revealed that the company is seeking next-generation obesity drug candidates.&nbsp;Shares of Viking spiked on the news, despite Novartis’s own obesity program being in the early stages of development, with no human clinical trials yet.Retail traders on Stocktwits are also bullish on the possibility of a merger or acquisition, especially as Viking’s shares have fallen by over 50% in the past three months.&nbsp;Notably, short interest on Viking has surged from 11.9% in mid-November to over 18% by the end of January.Wall Street’s average price target for Viking is $105.73, representing an upside of more than 230% from current levels.Morgan Stanley analysts, in a note on Thursday, said that after meeting with Viking's management, the company remains confident in securing a commercial manufacturing contract for subcutaneous VK2735, supporting a multibillion-dollar opportunity.The brokerage reiterated its 'Overweight' for the stock and its price target of $105.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.

Equity

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.


VONG
Vanguard Russell 1000 Growth Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VONG News

VONGVanguard Russell 1000 Growth Index ETF